ArticleJournal of natural medicines2016
Polygonatum stenophyllum improves menopausal obesity via regulation of lipolysis-related enzymes.
Article in Journal of natural medicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolomics Study of Different Germplasm Resources for ThreeFrontiers in plant science · 2022Article
- The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menopausal women are associated with an increase in obesity accompanying changes in the body's condition and composition. Polygonatum stenophyllum (PS) rhizome, which is a traditional herbal remedy, has been used to treat various diseases including obesity. However, the effect of PS on menopausal obesity remains unclear. Female C57BL/6 mice were ovariectomized (OVX) and fed on high fat diet (HFD) to induce menopausal obesity. Aqueous extract of PS of 1, 10, and 100 mg/kg was orally administrated for 6 weeks after 7 weeks of induction. The weights of body, uterine, and ovarian fat were investigated. Histological analysis was performed to monitor the changes of liver and fat. In addition, lipid profiles were measured in serum and the expression of lipolysis-related enzymes was analyzed in uterine tissues. PS significantly decreased the weights of body and ovarian fat and increased the uterine weight compared to control group. Administration of PS significantly decreased the adipocyte diameter and the lipid droplets within the hepatocytes. In addition, PS-treated mice had lower levels of triglyceride (TG), total cholesterol, and LDL-cholesterol than control mice. The expression of lipolysis-related genes, including adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), was increased in PS-treated groups. Taken together, these results demonstrate that PS might have efficacy on menopausal obesity by activating ATGL and HSL.
Indexed as
Identifiers
27324797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.